A phase 2, multi-center, open-label, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade) and bortezomib alone in subjects with relapsed or refractory multiple myeloma.

Trial Profile

A phase 2, multi-center, open-label, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade) and bortezomib alone in subjects with relapsed or refractory multiple myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Bortezomib; Mapatumumab
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Jun 2011 Results were presented at the 16th Congress of the European Hematology Association.
    • 17 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Mar 2011 Planned end date changed from 1 Oct 2008 to 1 Oct 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top